ArticlePakistan journal of medical sciences
A clinical study on clinical features,manifestations and drug resistance of melioidosis.
Article in Pakistan journal of medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 3 citations in OpenAlex.
- [⁶⁸Ga]Ga-FAPI-46 PET/CT imaging in neuromelioidosis: a case series demonstrating potential utility in diagnosis and response assessment.EJNMMI reports · 2026Article
- C-Reactive Protein for Early Diagnosis and Severity Monitoring in Melioidosis: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2025Review
- Global Prevalence of Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To explore the clinical features, manifestations and drug resistance of melioidosis. Methods: The clinical data of 45 melioidosis patients treated by Affiliated Haikou Hospital of Xiangya Medical College, Central South University during January 2015 and January 2020 were studied. Informaiton collected included age, birthplace, area of residence, sex, ethnic group, clinical symptoms or signs, colony culture results, degree of drug resistance, treatment regimens and outcomes, department of initial diagnosis, and specimen type, thereby giving an analysis of the clinical features, manifestations, and treatment outcomes of the disease. Body fluids were obtained from all patients to analyze the drug resistance of the bacterium Results: In the 45 cases of melioidosis, the clinical manifestations predominantly included low fever (31.11%), pulmonary infection (22.22%); auxiliary examinations often suggested increases in C reactive protein (CRP) (73.33%), white blood cell count (#WBC) (68.89%) and procalcitonin (PCT) (66.67%); susceptibility test results showed that Burkholderia pseudomallei yielded high sensitive rate to antibacterials including trimethoprim-sulfamethoxazole (SXT) (88.89%),ceftazidime (CAZ)(93.33%), meropenem (MEM) (100.00%), imipenem (IPM)(100.00%); Of the 45 melioidosis patients, 23 were cured (51.11%), and 21 showed an improvement (33.33%) or remained stable (13.33%); A relatively high percentage of the patients experienced post-discharge recurrence/aggravation (recurrence within six months: 4.44%; recurrence within a year: 6.67%). Conclusions: Low fever, pulmonary infection, and increases in serum inflammatory markers are major clinical features of melioidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.